The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
How do you see tandem CAR T-cell therapies fitting into the future treatment landscape for LBCL?
The Lymphoma Hub was pleased to speak with Ulrich Jäger, Medical University of Vienna, AT. We asked, How do you see tandem CAR T-cell therapies fitting into the future treatment landscape for LBCL?
In this interview, Jäger discusses the potential role of CD19/CD20-targeted chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). He explores the rationale for targeting both CD19 and CD20, highlights clinical data with zamtocabtagene autoleucel, and considers how tandem CAR T-cell therapies may address unmet needs in R/R LBCL. Finally, he discusses how these approaches may fit into the future treatment landscape for patients with LBCL.
Intended for healthcare professionals. This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
8 Oct 2026
What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL?
The Lymphoma Hub was pleased to speak with Christopher P. Fox, University of Nottingham, UK. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL?
In this interview, Fox discusses the 3-year follow-up results from the global, randomized, phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) (n = 183) vs rituximab (R)-GemOx (n = 91) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), recently published in Blood Advances. He also explores outcomes across clinically relevant subgroups.
Intended for healthcare professionals. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
8 Oct 2026
How might key findings from the HD21 trial influence 1L treatment of advanced stage cHL?
The Lymphoma Hub was pleased to speak to Peter Borchmann, University Hospital Cologne, Cologne, DE. We asked, How might key findings from the HD21 trial influence 1L treatment of advanced stage cHL?
In this interview, Borchmann discusses results from the randomized, multicenter, phase III HD21 trial (NCT02661503), which evaluated positron emission tomography-guided brentuximab vedotin + etoposide + cyclophosphamide + doxorubicin + dacarbazine + dexamethasone (BrECADD; n = 751) vs bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisolone (eBEACOPP; n = 749) in adults aged ≤60 years with advanced-stage classical Hodgkin lymphoma.
Intended for healthcare professionals. This educational resource is independently supported by Takeda. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy (https://acast.com/privacy) for more information.
Who has been a guest on Lymphoma Hub
Names identified in recent episode analyses. Showing up to five guests.
Nirav Shah
Peter Borchmann
Francesc Bosch
Susan O’Brien
Farrukh Awan
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
YouTube views
597,144
Score snapshot 15 Sept 2025
Spotify
5.0 / 5
1 ratings
Podcast Authority Score: 43 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
52
Social presence
0
YouTube
86
Engagement
0
Contact Lymphoma Hub
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Lymphoma Hub?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
